Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics' stock price experienced several notable events in the past six months (August 2025 - February 2026). On February 6, 2026, the stock price gained 10.51%, though it had fallen by 16.87% over the preceding 10 days. Aprea Therapeutics announced early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, including a partial response observed in a dose-escalation trial, on January 29, 2026. Also on January 29, 2026, the company announced a private placement of common stock and warrants, priced at-the-market under Nasdaq rules, expected to generate approximately $5.6 million in gross proceeds. On February 4, 2026, Aprea Therapeutics appointed Eugene Kennedy, MD, as Chief Medical Advisor, and the company's price target was decreased by 23.08% to $6.80. The company reported its quarterly earnings on November 12, 2025, missing the consensus estimate, which led to the stock drifting 53.2% lower since the announcement. In a letter to shareholders issued on December 18, 2025, the CEO highlighted pipeline progress in 2025 and outlined plans for 2026. Earlier in the year, the company reported its fourth quarter and full year 2024 financial results on March 25, 2025, and first quarter 2025 financial results on May 15, 2025.

As a clinical-stage biopharmaceutical company, Aprea Therapeutics, Inc. is primarily focused on research and development of novel cancer therapeutics. Its products are not yet commercialized, and therefore, there is no indication of demand seasonality for its products or services.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer by exploiting vulnerabilities in cancer cells while minimizing harm to healthy cells. The company is dedicated to precision oncology through synthetic lethality, targeting specific cancer-related genetic mutations. The company's lead product candidates, APR-1051 and ATRN-119, are in clinical development for solid tumor indications. Aprea's technology has potential applications across various cancer types, including ovarian, endometrial, colorectal, prostate, and breast cancers.

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, and was founded in Boston, Massachusetts. The available information primarily details its operational base within the United States, without specifying a broader international geographic footprint for its business operations or market reach at this clinical stage.

Aprea Therapeutics has received a "Hold" consensus rating from analysts, based on two buy ratings and two sell ratings. There is no specific information available in the provided search results detailing events that have significantly impacted the company's brand reputation, either positively or negatively, beyond the general sentiment reflected in stock performance and clinical trial updates.

Aprea Therapeutics, Inc. has a mixed ownership structure. Approximately 21.10% of the company's stock is owned by institutional investors, 10.23% by insiders, and 68.67% by public companies and individual investors. Major institutional shareholders include AIGH Capital Management LLC, Sphera Funds Management Ltd., Nantahala Capital Management, LLC, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), DAFNA Capital Management LLC, Sio Capital Management, LLC, Morgan Stanley, Vanguard Group Inc, Geode Capital Management, Llc, and Vanguard Extended Market Index Fund Investor Shares (VEXMX). Laurence Lytton and Oren Gilad (CEO) are also listed among the top shareholders.